PA
BNTC icon

Parallel Advisors’s Benitec Biopharma BNTC Stock Holding History

Parallel Advisors’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-55
Closed -$741 – 3843
2025
Q4 		$741 Buy
+55
New +$761 ﹤0.01% 3350

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Parallel Advisors's BNTC Position: Q1 2026 in Review

Parallel Advisors sold out of Benitec Biopharma (BNTC) in Q1 2026, closing a stake of 55 shares — an estimated $741 sold.

Parallel Advisors first reported a position in BNTC in Q4 2025 and held it in 1 quarter. The position peaked at $741 in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • Parallel Advisors reported no remaining Benitec Biopharma position as of Q1 2026 after selling out during the quarter.
  • Parallel Advisors sold 55 Benitec Biopharma shares in Q1 2026, an estimated $741.
  • Parallel Advisors first reported a position in Benitec Biopharma in Q4 2025 and held it in 1 quarter.
  • Parallel Advisors's Benitec Biopharma position peaked at $741 in Q4 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.